Redx Pharma plc, of Cheshire, U.K., reported that its porcupine enzyme inhibitor and new lead candidate, RX-C006, was able to suppress lung fibrosis, in vivo in a preclinical model. The drug suppressed the release of Wnt-5a from human lung fibroblasts at nanomolar concentrations and reduced fibroblast activation. Redx is developing it for the potential oral treatment of idiopathic pulmonary fibrosis.